The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Flavopiridol: the First Cyclin-Dependent Kinase Inhibitor in Human Clinical Trials
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
CDK inhibitors: positive and negative regulators of G1-phase progression
Sherr, C. J., & Roberts, J. M. (1999) · Genes & Development · doi:10.1101/gad.13.12.1501 · Cited by 6,115
Sherr, C. J. (1996) · Science · doi:10.1126/science.274.5293.1672 · Cited by 5,379 · cited 2×
“Cdk2/cyclin A is required for progression through S phase, and cdk1 (also known as cdc2) combined with cyclin B is necessary for mitosis to occur [1].”
BackgroundThe retinoblastoma protein and cell cycle control
Weinberg, R. A. (1995) · Cell · doi:10.1016/0092-8674(95)90385-2 · Cited by 4,862
The regulation of E2F by pRB-family proteins.
Dyson, N. (1998) · Genes & Development · doi:10.1101/gad.12.15.2245 · Cited by 2,317
CYCLIN-DEPENDENT KINASES: Engines, Clocks, and Microprocessors
Morgan, D. O. (1997) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.13.1.261 · Cited by 2,259
Horder, & Harnett, W. L. (1941) · BMJ · doi:10.1136/bmj.1.4186.493 · Cited by 1,314
Wei, P., Garber, M. E., Fang, S.-M., Fischer, W. H., & Jones, K. A. (1998) · Cell · doi:10.1016/s0092-8674(00)80939-3 · Cited by 1,249
Graña, X., & Reddy, E. P. (1995) · PubMed · Cited by 1,139
Exploiting Chemical Libraries, Structure, and Genomics in the Search for Kinase Inhibitors
Gray, N. S., Wodicka, L., Thunnissen, A.-M. W. H., Norman, T. C., Kwon, S., Espinoza, F. H., Morgan, D. O., Barnes, G., LeClerc, S., Meijer, L., et al. (1998) · Science · doi:10.1126/science.281.5376.533 · Cited by 808
Proceedings of the American Association for Cancer Research.
Konings, E. J. M., van den Brandt, P. A., Saris, W. H. M., Brants, H. A. M., & Goldbohm, R. A. (2001) · Cited by 764
Carlson, B. A., Dubay, M., Sausville, E. A., Brizuela, L., & Worland, P. J. (1996) · PubMed · Cited by 580
Identification of multiple cyclin subunits of human P-TEFb
Peng, J., Zhu, Y., Milton, J. T., & Price, D. H. (1998) · Genes & Development · doi:10.1101/gad.12.5.755 · Cited by 519
De Azevedo, W. F., Mueller-Dieckmann, H. J., Schulze-Gahmen, U., Worland, P. J., Sausville, E., & Kim, S. H. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.7.2735 · Cited by 496
Clinical pharmacology and therapeutics
Fenn, G. C. (1990) · Postgraduate Medical Journal · doi:10.1136/pgmj.66.778.686 · Cited by 479
Senderowicz, A. M., Headlee, D., Stinson, S. F., Lush, R. M., Kalil, N., Villalba, L., Hill, K., Steinberg, S. M., Figg, W. D., Tompkins, A., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.9.2986 · Cited by 403
Self-citationFredersdorf, S., Burns, J., Milne, A. M., Packham, G., Fallis, L., Gillett, C. E., Royds, J. A., Peston, D., Hall, P. A., Hanby, A. M., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.12.6380 · Cited by 357
Michalides, R. J. A. M., van Veelen, N., Hart, A. A. M., Loftus, B. M., Wientjens, E., & Balm, A. J. M. (1995) · PubMed · Cited by 352
Zhang, H. S., Postigo, A. A., & Dean, D. C. (1999) · Cell · doi:10.1016/s0092-8674(00)80714-x · Cited by 349
Growth Inhibition With Reversible Cell Cycle Arrest of Carcinoma Cells by Flavone L86-8275
Kaur, G., Stetler-Stevenson, M., Sebers, S., Worland, P., Sedlacek, H., Myers, C., Czech, J., Naik, R., & Sausville, E. (1992) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/84.22.1736 · Cited by 346
Potent Inhibition of Cdc2 Kinase Activity by the Flavonoid L86-8275
Losiewicz, M. D., Carlson, B. A., Kaur, G., Sausville, E. A., & Worland, P. J. (1994) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1994.1742 · Cited by 345
Cyclins, Cyclin-Dependent Kinases and Cdk Inhibitors: Implications in Cell Cycle Control and Cancer
MacLachlan, T. K., Sang, N., & Giordano, A. (1995) · Critical Reviews in Eukaryotic Gene Expression · doi:10.1615/critreveukargeneexpr.v5.i2.20 · Cited by 309
Carlson, B., Lahusen, T. J., Singh, S., Loaiza‐Perez, A., Worland, P. J., Pestell, R. G., Albanese, C., Sausville, E. A., & Senderowicz, A. M. (1999) · PubMed · Cited by 287
Self-citationByrd, J. C., Shinn, C., Waselenko, J. K., Fuchs, E. J., Lehman, T. A., Nguyen, P. L., Flinn, I. W., Diehl, L. F., Sausville, E., & Grever, M. R. (1998) · Blood · doi:10.1182/blood.v92.10.3804 · Cited by 283
Flavopiridol (L86 8275; NSC 649890), a new kinase inhibitor for tumor therapy
Sedlacek, H., Czech, J., Naik, R., Kaur, G., Worland, P., Losiewicz, M., Parker, B., Carlson, B., Smith, A., Senderowicz, A., et al. (1996) · International Journal of Oncology · doi:10.3892/ijo.9.6.1143 · Cited by 275
Self-citationOverexpression of cyclin D1 in human pancreatic carcinoma is associated with poor prognosis.
Gansauge, S., Gansauge, F., Ramadani, M., Stobbe, H., Rau, B., Harada, N., & Beger, H. G. (1997) · PubMed · Cited by 261
Bible, K. C., & Kaufmann, S. H. (1997) · PubMed · Cited by 258
Tassan, J. P., Schultz, S. J., Bartek, J., & Nigg, E. A. (1994) · The Journal of cell biology · doi:10.1083/jcb.127.2.467 · Cited by 251
Park, D. S., Farinelli, S. E., & Greene, L. A. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.14.8161 · Cited by 250
Patel, V, Senderowicz, A. M., Pinto, D., Igishi, T., Raffeld, M., Quintanilla-Martinez, L., Ensley, J. F., Sausville, E. A., & Gutkind, J. S. (1998) · Journal of Clinical Investigation · doi:10.1172/jci3661 · Cited by 246
Self-citationArguello, F., Alexander, M., Sterry, J. A., Tudor, G., Smith, E. M., Kalavar, N. T., Greene, J. F., Koss, W., Morgan, C. D., Stinson, S. F., et al. (1998) · PubMed · doi:10.1182/blood.v91.7.2482 · Cited by 240
Graña, X., De Luca, A., Sang, N., Fu, Y., Claudio, P. P., Rosenblatt, J., Morgan, D. O., & Giordano, A. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.9.3834 · Cited by 231
König, A., Schwartz, G. K., Mohammad, R. M., Al-Katib, A., & Gabrilove, J. L. (1997) · Blood · doi:10.1182/blood.v90.11.4307 · Cited by 191
Bible, K. C., & Kaufmann, S. H. (1996) · PubMed · Cited by 189
Cyclins and Cyclin-Dependent Kinases: Theme and Variations
(1995) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)60254-7 · Cited by 172
The role of RB in cell cycle control
Hatakeyama, M., & Weinberg, R. A. (1995) · Progress in Cell Cycle Research · doi:10.1007/978-1-4615-1809-9_2 · Cited by 164
Cyclin C/CDK8 is a novel CTD kinase associated with RNA polymerase II.
Rickert, P., Seghezzi, W., Shanahan, F., Cho, H. K., & Lees, E. M. (1996) · PubMed · Cited by 160
Melillo, G., Sausville, E. A., Cloud, K., Lahusen, T. J., Varesio, L., & Senderowicz, A. M. (1999) · PubMed · Cited by 142
Self-citationWorland, P. J., Kaur, G., Stetler‐Stevenson, M., Sebers, S., Sartor, O. A., & Sausville, E. A. (1993) · Biochemical Pharmacology · doi:10.1016/0006-2952(93)90590-s · Cited by 141
Cyclin-Dependent KinasesInitial Approaches to Exploit a Novel Therapeutic Target
Sausville, E. A., Zaharevitz, D. W., Gussio, R., Meijer, L., Leost, M., Kunick, C., Schultz, R. J., Lahusen, T. J., Headlee, D. J., & Stinson, S. F. (1999) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(98)00062-x · Cited by 117
Human and Yeast Cdk-activating Kinases (CAKs) Display Distinct Substrate Specificities
Kaldis, P., Russo, A. A., Chou, H. S., Pavletich, N. P., & Solomon, M. J. (1998) · Molecular Biology of the Cell · doi:10.1091/mbc.9.9.2545 · Cited by 109
Edwards, M. C., Wong, C., & Elledge, S. J. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.7.4291 · Cited by 102
Cell Cycle and Cancer: Critical Events at the G1 Restriction Point
DelSal, G., Loda, M. F., & Pagano, M. (1996) · Critical Reviews™ in Oncogenesis · doi:10.1615/critrevoncog.v7.i1-2.80 · Cited by 77
Jäger, W. R., Zembsch, B., Wolschann, P., et al. (1998) · Life Sciences · doi:10.1016/s0024-3205(98)00152-0 · Cited by 71
Clinical pharmacology and therapeutics
Matzke, G. R. (2005) · Taylor & Francis eBooks · doi:10.3109/9780203024829-26 · Cited by 65
Lee, H. R., Chang, T. H., Tebalt, M. J., Senderowicz, A. M., & Szabo, E. M. (1999) · International Journal of Oncology · doi:10.3892/ijo.15.1.161 · Cited by 45
Self-citationControl of eukaryotic cell cycle progression by phosphorylation of cyclin-dependent kinases.
Morgan, D. O., Fisher, R. P., Espinoza, F. H., Farrell, A., Nourse, J. L., Chamberlin, H., & Jin, P. (1998) · PubMed · Cited by 43
Clinical trials referral resource. Clinical trials of flavopiridol.
Wright, J., Blatner, G. L., & Cheson, B. D. (1998) · PubMed · Cited by 30
Cited by
Flavonoids: Promising anticancer agents
Ren, W., Qiao, Z., Wang, H., Zhu, L., & Zhang, L. (2003) · Medicinal Research Reviews · doi:10.1002/med.10033 · Cited by 1,150
Galati, G., & O'Brien, P. J. (2004) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2004.04.034 · Cited by 1,099
Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2)
Austin Doyle, L., & Ross, D. D. (2003) · Oncogene · doi:10.1038/sj.onc.1206938 · Cited by 1,051
Discovery of drug mode of action and drug repositioning from transcriptional responses
Iorio, F., Bosotti, R., Scacheri, E., Belcastro, V., Mithbaokar, P., Ferriero, R., Murino, L., Tagliaferri, R., Brunetti-Pierri, N., Isacchi, A., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1000138107 · Cited by 816
Flavonoids: A versatile source of anticancer drugs
Sharma, N., Dobhal, M., Joshi, Y., & Chahar, M. (2011) · Pharmacognosy Reviews · doi:10.4103/0973-7847.79093 · Cited by 551
Metadata
- Authors
- Senderowicz, A. M.
- Venue
- Investigational New Drugs
- Published
- 1999-08
- Volume
- 17
- Issue
- 3
- Pages
- 313-320
- ISSN
- 0167-6997 (ISSN-L)
- 1573-0646
- OpenAlex
- W1495058242
- Cited by
- 330
- References
- 47
- FWCI
- 4.89
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.